Beta3 Adrenergic Agonist Activation of Hippocampal Precursors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches fail to directly activate latent neural precursor cells, which are crucial for replacing damaged neurons in neurological diseases such as Alzheimer's, stroke, depression, and Parkinson's, due to the inability to dissect direct versus non-cell-autonomous effects of neurotransmitters like serotonin and norepinephrine on these cells.
Innovation Solution
Activation of adult hippocampal precursors by norepinephrine in neurosphere-forming media, mediated by β3 adrenergic receptors, which are exclusively expressed by this neurogenic precursor pool, using β3 adrenergic receptor agonists to stimulate proliferation and differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If neurotransmitters like serotonin and norepinephrine are used to activate latent neural precursor cells, then neuron replacement may be achieved, but the inability to dissect direct versus non-cell-autonomous effects limits treatment precision
Solution Approach 1:
The patent segments the adrenergic receptor system into specific subtypes (β1, β2, β3) and identifies that latent neural precursor cells specifically express β3 adrenergic receptors. This segmentation allows selective activation using β3-specific agonists, thereby dissecting the direct effects on precursor cells from non-cell-autonomous effects on other cell types.
Solution Approach 2:
The invention applies local quality by targeting a specific receptor subtype (β3 adrenergic receptor) that is locally expressed only on latent neural precursor cells, rather than using general neurotransmitters that act on multiple cell types. This localized targeting enables precise activation of the desired cell population.
2Productivity
If general adrenergic agonists are used to stimulate neural precursor cells, then broad activation may occur, but off-target effects on other cell types reduce treatment specificity
Solution Approach 1:
The patent changes the parameter of receptor specificity by shifting from general adrenergic agonists that activate multiple receptor subtypes to selective β3 adrenergic receptor agonists. This parameter change maintains activation efficiency for neural precursor cells while eliminating off-target effects on other cell types that express different adrenergic receptor subtypes.
3Reliability
If stem cell transplantation is used to replace lost neurons, then neuron replacement can be achieved, but the invasive nature and complexity of transplantation procedures increase treatment difficulty
Solution Approach 1:
The invention enables self-service by activating the patient's own latent neural precursor cells in situ through pharmacological stimulation with β3 adrenergic receptor agonists. This eliminates the need for external stem cell transplantation procedures, allowing the body's own repair mechanisms to be harnessed directly.
Solution Approach 2:
The patent introduces a chemical intermediary (β3 adrenergic receptor agonist) that mediates the activation of latent neural precursor cells. This intermediary approach replaces the need for surgical transplantation procedures with a pharmacological intervention that triggers endogenous cell activation and differentiation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively activates latent neural precursor cells, enhancing their self-renewal and multipotency, and is applicable for screening candidate pharmaceuticals and treating neurodegenerative diseases by stimulating the in vivo population to proliferate and differentiate, potentially reversing neuron loss in these conditions.
Implementation Method 1
Activation of adult hippocampal precursors by norepinephrine in neurosphere-forming media, mediated by β3 adrenergic receptors
Data Source
AI summary
A method of activating a latent neural precursor cell population, comprising: (1) providing a neural cell population derived from the hippocampus; (2) introducing the neural cell population to a neurosphere-forming culture medium; and (3) activating the latent precursor cell population by treatment with a β3 adrenergic receptor agonist.